-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 12, 2022, Takeda and Engitix entered into an agreement to expand an existing collaboration to the discovery and development of fibro-stenotic inflammatory bowel disease (IBD), including new treatments for Crohn's disease and ulcerative colitis
Takeda is the first and only Asian company to be ranked among the top 10 global pharmaceutical companies
Engitix's R&D pipeline
The ECM platform is applicable to multiple organs, indications and fields
Fibrotic strictures are fibrotic obstructions caused by intestinal inflammation, most commonly seen in Crohn's disease (CD) in IBD
According to the report of GrandViewer Search, the overall market size of IBD was 15.
CD can involve the entire gastrointestinal tract and is a discontinuous full-thickness inflammation, most often involving the terminal ileum, colon, and perianal region
In the face of such a huge digestion market, whether Takeda can open up a new situation for future development by expanding cooperation, let us stay tuned!
Original in English: https://engitix.
https://engitix.
com/engitix-announces-expanded-collaboration-and-licensing-agreement-with-takeda-to-develop-new-anti-fibrotic-therapies-in-inflammatory-bowel-disease/